IVF Reads / Male Infertility Genetic Tests: Who Needs Them and What Results Change

Male Infertility Genetic Tests: Who Needs Them and What Results Change

M
Written by MayaPublished Updated
Genetic Causes of Male Infertility
AI summary

Genetic testing in male infertility is targeted, not routine. The European Association of Urology (EAU Guidelines 2026) recommends a karyotype for men with azoospermia or a sperm concentration under 5 million/mL, Y-chromosome microdeletion testing at or below 1 million/mL (considered under 5 million/mL), and CFTR testing of both partners when the vas deferens is absent. The results decide whether surgical sperm retrieval is worth attempting and what a child may inherit.

  • EAU Guidelines 2026: perform Y-chromosome microdeletion testing in men with sperm concentrations of 1 million/mL or less, and consider it below 5 million/mL; offer karyotype and genetic counselling to men with azoospermia or oligozoospermia below 5 million/mL.
  • Complete deletions that include the AZFa and AZFb regions predict no sperm at surgery: in Hopps et al. (Hum Reprod 2003), none of 36 men with AZFa, AZFb, AZFb+c or AZFa+b+c deletions had sperm found. The EAU advises against testicular sperm extraction in these men.
  • With an isolated AZFc deletion, micro-TESE found sperm in 275 of 441 men (62.4%) across 11 cohort studies (Jiao et al., BJU Int 2024), and any son conceived with those sperm inherits the deletion (EAU 2026).
  • In Klinefelter syndrome, a meta-analysis of 37 studies and 1,248 men found sperm in 44% per TESE cycle, with no difference between micro-TESE and conventional TESE (Corona et al., Hum Reprod Update 2017).
  • 78% of men with congenital bilateral absence of the vas deferens carry at least one CFTR mutation (Yu et al., Hum Reprod 2012 meta-analysis). In an Indian cohort, 13 of 80 female partners also carried a CFTR variant (Gaikwad et al., Indian J Med Res 2020).

Does every man with a poor semen report need a genetic test?

No. Genetic testing is aimed at a specific group: men with no sperm in the ejaculate (azoospermia), men with a very low sperm concentration, and men in whom one or both vas deferens tubes are missing. A man with mildly reduced motility or morphology is very unlikely to have one of these findings, and the guidelines do not recommend testing him for them.

The European Association of Urology guideline (EAU 2026, Male Infertility chapter) sets out the thresholds. They are worth knowing, because the right test depends on the count, and counts are only meaningful after at least two semen analyses if the first was abnormal, which the same guideline requires.

  • Karyotype (a chromosome count from a blood sample): offered with genetic counselling to men with azoospermia or oligozoospermia below 5 million sperm/mL.
  • Y-chromosome microdeletion (AZF) test: performed when the sperm concentration is 1 million/mL or less, and considered below 5 million/mL. A meta-analysis the EAU cites, of 12,492 oligozoospermic men in 37 studies, found under 1% of deletions above 1 million/mL.
  • CFTR (cystic fibrosis gene) test: for men with absence of the vas deferens on one or both sides without a kidney anomaly, and for their partners.

Two honest qualifications. The EAU's own supporting text gives 10 million/mL as the karyotype threshold, while its recommendation table says 5 million/mL; the lower figure is the formal recommendation. And the American AUA/ASRM guideline revised its Y-microdeletion thresholds in a 2024 amendment whose full text we could not retrieve, so its numbers are not repeated here.

Why test at all, if the plan is ICSI anyway?

Because ICSI only needs a few sperm, and the genetic result is often the best guide to whether those sperm exist and what they carry. A result can change three things: whether surgery to find sperm is worth attempting, whether the partner also needs testing, and what a child conceived with those sperm could inherit. All three are easier to weigh before an operation than after one.

Genetic testing comes after the basic workup, not instead of it: a repeat centrifuged semen sample, hormones and an examination come first. That sequence is covered in our azoospermia explainer.

What does a karyotype find, and what if it shows Klinefelter syndrome?

A karyotype counts the chromosomes and looks for large rearrangements. Abnormal results become more common as the count falls: the EAU reports that men with fewer than 5 million sperm/mL have about a ten-fold higher rate (4%) of mainly structural autosomal abnormalities than the general population, and men with non-obstructive azoospermia are at the highest risk, particularly of an extra X chromosome.

That extra X is Klinefelter syndrome (47,XXY). In the clinic series tabulated in the EAU guideline, it accounted for 13.7% of 1,446 azoospermic men, against 2.6% of 12,945 unselected patients. Often the only signs are infertility and small testes.

A Klinefelter result does not mean sperm cannot be found. Corona and colleagues pooled 37 studies and 1,248 men (Hum Reprod Update 2017): testicular sperm extraction found sperm in 44% per TESE cycle, with similar rates for micro-TESE and conventional TESE. Where sperm were used for ICSI, there were 218 pregnancies from 410 ICSI cycles, with a pooled live birth rate of 43% per ICSI cycle. Age, testis volume and hormone levels did not predict who would have sperm.

Klinefelter syndrome also needs care beyond fertility. The EAU recommends long-term endocrine follow-up, notes higher risks of metabolic and cardiovascular disease, and says testosterone therapy may be considered once fertility questions have been addressed, which is a reason to raise fertility plans before starting it.

A balanced translocation or inversion is the other common finding. It usually causes no symptoms in the man but raises the chance of embryos with an unbalanced set of chromosomes. The EAU advises genetic counselling for the couple, and preimplantation genetic testing or amniocentesis when IVF or ICSI goes ahead.

Sperm found in Klinefelter syndrome44% per TESE cyclePooled across 37 studies and 1,248 men (95% CI 39-48%). Micro-TESE and conventional TESE gave similar rates; no clinical or hormonal measure predicted success.Corona G et al. Sperm recovery and ICSI outcomes in Klinefelter syndrome: a systematic review and meta-analysis. Hum Reprod Update 2017;23(3):265-275. PMID 28379559.

What do AZFa, AZFb and AZFc deletions predict for sperm retrieval?

The Y chromosome carries three regions needed to make sperm, called AZFa, AZFb and AZFc. A missing region is invisible on a karyotype and needs its own test. The EAU reports deletions in 8% to 12% of azoospermic men and 3% to 7% of oligozoospermic men. They are the most frequent molecular genetic cause of severe oligozoospermia and azoospermia.

Which region is missing matters more than anything else about the result:

  • Complete AZFa, AZFb, AZFb+c or AZFa+b+c deletion: sperm are almost never found. Hopps and colleagues (Hum Reprod 2003) operated on or biopsied men with each of these patterns and found no sperm in any of the 36. The EAU's strong recommendation is not to perform testicular sperm extraction in men with complete deletions that include AZFa and AZFb.
  • Isolated AZFc deletion: sperm are often found, either in the ejaculate or the testis. The EAU gives a range of 50% to 75% for finding testicular sperm. A 2024 systematic review of 11 cohort studies found sperm at micro-TESE in 275 of 441 men (62.4%), with individual studies ranging from 25.0% to 85.7%.
  • Partial deletions: the EAU notes that clinically relevant deletions are usually complete. A partial deletion is interpreted by the laboratory and a genetic counsellor, not read off the same table.

The test itself is not interchangeable between laboratories. The 2023 EAA/EMQN laboratory guideline (Krausz et al., Andrology 2024) says many commercial kits are not recommended, and its external quality-control scheme saw a steep decline in diagnostic errors among participating laboratories over 22 years. Asking whether the laboratory takes part in such a scheme is reasonable.

Men with complete AZFa or AZFb-including deletions in whom sperm were found0 of 363 AZFa, 11 AZFb, 16 AZFb+c and 6 AZFa+b+c deletions. By contrast, 9 of 12 men with an isolated AZFc deletion had sperm at TESE.Hopps CV et al. Detection of sperm in men with Y chromosome microdeletions of the AZFa, AZFb and AZFc regions. Hum Reprod 2003;18(8):1660-5. PMID 12871878.

If sperm are found with an AZFc deletion, does ICSI work as well?

Possibly not quite as well, but the evidence disagrees. Colaco and Modi pooled case-control studies covering 3,807 men (Fertil Steril 2024). Compared with men without deletions, men with AZFc deletions had lower fertilisation (odds ratio 0.61) and a lower live birth rate (odds ratio 0.54, 95% CI 0.40-0.72). The higher sperm retrieval rate in the deletion group was not statistically significant.

The EAU, citing an earlier meta-analysis, says fertilisation is reduced but live birth rate is not. The two analyses cannot both be right, and the honest position is that a modest reduction is plausible and unproven. It is a reason to discuss expectations, not a reason to avoid ICSI.

If the vas deferens is missing, why does the partner need a CFTR test?

Because the child's risk depends on both parents. Congenital bilateral absence of the vas deferens (CBAVD) means sperm are made normally but have no route out, so the semen contains none. It is usually caused by variants in CFTR, the cystic fibrosis gene. The EAU notes these men often have only mild signs of cystic fibrosis, such as a history of chest infections.

The EAU puts CBAVD at about 1% of infertile men and up to 6% of men with obstructive azoospermia, and says it is easy to miss: every azoospermic man should be examined for it, particularly with semen volume under 1.0 mL and an acidic pH below 7.0. Sperm can be retrieved from the epididymis or testis for ICSI.

Yu and colleagues' meta-analysis (Hum Reprod 2012) found at least one CFTR mutation in 78% of men with CBAVD. If the female partner also carries a CFTR variant, the EAU puts the risk of a child with cystic fibrosis or CBAVD at up to 50%, depending on the variants. The EAU strongly recommends testing both.

Indian data make partner testing more important, not less. Gaikwad and colleagues sequenced the whole CFTR gene in 80 Indian men with CBAVD and their partners (Indian J Med Res 2020). Variants were found in 53 of the 80 men (66.3%), including eight not previously reported, and the authors found the spectrum differs from that in Caucasian men. Thirteen of the 80 female partners carried a mild or severe variant, and in nine couples both partners did. The authors note there is no India-specific CFTR panel, so a test built around common European mutations can miss variants seen here.

Indian female partners of men with CBAVD carrying a CFTR variant13 of 8016.2% of partners carried a mild or severe CFTR variant on full gene sequencing; in 9 of 80 couples both partners carried one.Gaikwad A et al. Cystic fibrosis transmembrane conductance regulator-related male infertility: relevance of genetic testing & counselling in Indian population. Indian J Med Res 2020;152(6):575-583. PMID 34145097.

What can a man pass on to his children?

This is where each result has a different answer, and it is the core of genetic counselling before ICSI.

  • Y-chromosome AZF deletion: a son conceived with these sperm inherits the deletion. The EAU's strong recommendation is that couples are told this before ICSI.
  • CFTR variants: the child's risk of cystic fibrosis or CBAVD depends on what the partner carries, which is why she is tested.
  • Klinefelter syndrome: a 2025 Danish review (Fedder et al.) reports that sperm found in these men come from cell lines with a normal chromosome number, and that their children usually have a normal karyotype.
  • Balanced translocations: a risk of embryos with unbalanced chromosomes and of miscarriage, which is what preimplantation testing or prenatal testing is used to address.

How these results bear on the wider family, including siblings and the partner's own genetics, is covered in genetics in couple infertility, and what a counselling appointment involves in genetic counselling for male infertility.

When is donor sperm the realistic option?

When the result says surgery cannot succeed, or surgery has been tried and found nothing. A complete AZFa or AZFb-including deletion is the clearest case: the guideline advice is not to operate. Donor sperm may also be considered by couples who would rather not pass on an AZF deletion or who both carry CFTR variants. These are choices for the couple after counselling, not defaults.

When donor sperm becomes the question is covered in when to consider donor sperm or eggs, the Indian rules on donation in donor egg and sperm rules in India, and the retrieval procedures themselves in what TESE is and when it is used.

What the evidence does not establish

  • A normal genetic result does not mean a cause has been excluded. Known genetic anomalies explain only around 25% of non-obstructive azoospermia (Cervan-Martin et al., J Clin Med 2020). The EAU says exome sequencing is finding more causes but is not yet validated for standard clinical use.
  • Nothing reliably predicts sperm retrieval in Klinefelter syndrome. Corona 2017 found no effect of age, testis volume or hormones; the EAU notes some evidence that younger men do better but says no age threshold can be given.
  • Whether an AZFc deletion lowers the live birth rate after ICSI is disputed between two meta-analyses, described above.
  • The gr/gr partial AZFc deletion is a population-specific risk factor for reduced sperm production, and testing for it is left to the laboratory and clinician (Krausz et al. 2024). Its significance for an individual man is not settled.
  • The EAU's figure of about 0.4% residual risk for a partner who tests negative is not drawn from Indian data, and the Indian CFTR evidence rests on single-centre cohorts of around 80 men. A reliable residual risk for Indian couples has not been established.
  • Guideline thresholds differ. The EAU's text and table disagree on the karyotype cut-off, and the 2024 AUA/ASRM revision of Y-deletion thresholds could not be checked for this page.

A genetic result can feel like a verdict on something nobody chose. It is better read as information that arrives early enough to shape the next decision, which is when it is most useful.

Have a genetic result you want explained?

Our team can go through what the report says, what it does and does not change, and which questions to take to a genetic counsellor.

Keep reading

11 Sources

  1. European Association of Urology. EAU Guidelines on Sexual and Reproductive Health, 2026 edition (a limited update of 2025 that did not revise the male infertility chapter), Chapter 11 Male Infertility. Recommendations: offer karyotype and genetic counselling to men with azoospermia and oligozoospermia <5 million/mL (the supporting text gives <10 million/mL); perform Y-microdeletion testing at <=1 million/mL and consider it <5 million/mL; inform men with Yq microdeletions that deletions pass to sons; do not perform TESE with complete deletions including AZFa and AZFb; test men with absent vas (no renal anomaly) and their partners for CFTR. Text: Y deletions in 8-12% of azoospermic and 3-7% of oligozoospermic men; AZFc testicular sperm in 50-75%; CBAVD in 1% of infertile men and up to 6% with obstructive azoospermia; Klinefelter 13.7% of 1,446 azoospermic men in the tabulated series; Klinefelter TESE/mTESE retrieval up to 50%. European Association of Urology
  2. Brannigan RE, Hermanson L, Kaczmarek J, et al. Updates to Male Infertility: AUA/ASRM Guideline (2024). J Urol. 2024;212(6):789-799. PMID 39145501. Amends the 2020 AUA/ASRM guideline (Schlegel PN et al., J Urol 2021;205:36-43, PMID 33295257), including revised thresholds for Y-chromosome microdeletion testing. Abstract only retrieved; full statements not accessed. American Urological Association / ASRM
  3. Krausz C, Navarro-Costa P, Wilke M, Tuttelmann F. EAA/EMQN best practice guidelines for molecular diagnosis of Y-chromosomal microdeletions: state of the art 2023. Andrology. 2024;12(3):487-504. PMID 37674303. Many commercial kits not recommended; gr/gr partial AZFc deletion a population-specific risk factor and predisposing factor for testicular germ cell tumours; 22 years of external quality assessment showed a steep decline in diagnostic errors. Andrology (European Academy of Andrology)
  4. Hopps CV, Mielnik A, Goldstein M, Palermo GD, Rosenwaks Z, Schlegel PN. Detection of sperm in men with Y chromosome microdeletions of the AZFa, AZFb and AZFc regions. Hum Reprod. 2003;18(8):1660-5. PMID 12871878. 78 men; no sperm found in any with AZFa (3), AZFb (11), AZFb+c (16) or AZFa+b+c (6) deletions; isolated AZFc: sperm in 9 of 12 at TESE and 9 of 20 on biopsy. Human Reproduction
  5. Jiao ZY, Li MR, Zhuo L, Fang YY, Pan JY, Hong K. Sperm retrieval rate and patient factors in azoospermia factor c microdeletion azoospermia: a systematic review. BJU Int. 2024;134(1):6-12. PMID 37942695. 11 cohort studies; sperm at micro-TESE in 275 of 441 men (62.4%), range 25.0%-85.7%. BJU International
  6. Colaco S, Modi D. Azoospermia factor c microdeletions and outcomes of assisted reproductive technology: a systematic review and meta-analysis. Fertil Steril. 2024;121(1):63-71. PMID 37923163. 3,807 men; sperm retrieval OR 1.82 (95% CI 0.97-3.41, not significant); fertilisation OR 0.61 (0.50-0.74); live birth OR 0.54 (0.40-0.72) versus men without deletions. Fertility and Sterility
  7. Corona G, Pizzocaro A, Lanfranco F, et al. Sperm recovery and ICSI outcomes in Klinefelter syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2017;23(3):265-275. PMID 28379559. 37 studies, 1,248 men; retrieval 44% (95% CI 39-48) per TESE cycle; mTESE vs cTESE similar; 218 pregnancies from 410 ICSI cycles; live birth rate 43% per ICSI cycle; no predictor among age, testis volume, FSH, LH or testosterone. Human Reproduction Update
  8. Yu J, Chen Z, Ni Y, Li Z. CFTR mutations in men with congenital bilateral absence of the vas deferens (CBAVD): a systemic review and meta-analysis. Hum Reprod. 2012;27(1):25-35. PMID 22081250. 78% of men with CBAVD had at least one CFTR mutation, 46% two. Human Reproduction
  9. Gaikwad A, Khan S, Kadam S, et al. Cystic fibrosis transmembrane conductance regulator-related male infertility: relevance of genetic testing & counselling in Indian population. Indian J Med Res. 2020;152(6):575-583. PMID 34145097. Full CFTR sequencing in 80 Indian men with CBAVD and partners: variants in 53 men (66.3%); 13 of 80 partners (16.2%) carried a mild or severe variant; 9 couples both carriers; no population-specific panel available in India. Indian Journal of Medical Research (ICMR)
  10. Cervan-Martin M, Castilla JA, Palomino-Morales RJ, Carmona FD. Genetic landscape of nonobstructive azoospermia and new perspectives for the clinic. J Clin Med. 2020;9(2):300. PMID 31973052. Known genetic anomalies explain around 25% of non-obstructive azoospermia. Journal of Clinical Medicine
  11. Fedder J, Skakkebaek A, Jensen CFS, Gravholt CH. [Fertility treatment of men with Klinefelter syndrome]. Ugeskr Laeger. 2025;187(12). PMID 40152162. Narrative review in Danish; English abstract only read. Sperm found in 42% of 93 Danish men operated on; few men have fathered children with ejaculated sperm; children usually have a normal karyotype. Ugeskrift for Laeger

Frequently asked questions

Questions this page has not already answered above.

Are these tests done on blood or on semen?

Karyotype, Y-chromosome microdeletion and CFTR tests are run on DNA from a blood sample, not on semen. The EAU describes testing of sperm chromosomes as a separate test used only in selected cases, such as recurrent miscarriage.

Does a Y-chromosome deletion raise the risk of testicular cancer?

Complete (classical) AZF deletions do not, according to the EAU guideline. The partial gr/gr deletion is different: the 2023 EAA/EMQN laboratory guideline describes it as a predisposing factor for testicular germ cell tumours.

Can a man with Klinefelter syndrome have sperm in his semen?

Occasionally. Most men with Klinefelter syndrome have no sperm in the ejaculate, and the 2025 Danish review by Fedder and colleagues reports that only a few have fathered children with ejaculated sperm. The EAU notes sperm production is seen more often in men with the mosaic 46,XY/47,XXY form.

Does it matter which laboratory runs the Y-deletion test?

It can. The EAA/EMQN guideline strongly encourages annual participation in external quality control, and reports a steep decline in diagnostic errors among laboratories in its scheme. A result that would cancel an operation deserves a laboratory that participates.

If both partners carry a CFTR variant, is ICSI still possible?

Yes, but the EAU says the couple must consider carefully whether to proceed, because the child's risk can reach 50% depending on the variants. This is a decision for genetic counselling, where options including donor sperm can be discussed.